The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as ...

While the accelerated approval pathway has enabled faster access to promising oncology drugs, meaningful improvements in survival or quality of life often remain unproven, even after full approval,” ...

The FDA has decided not to approve vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

The study results “indicate that the public has certain reservations about the integration of AI in health care,” the researchers wrote.

Resources available to clinical research physicians and the expectations placed upon these individuals vary across cancer cancers, data suggest.

This analysis indicates that proposed Medicaid reforms would have far-reaching consequences beyond federal budget savings, including negative health outcomes, economic losses, and health care system ...

Researchers assessed the global burden of breast cancer in boys and men aged 15-64 years between 1990 and 2021.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

The Trump administration’s immigration policies are having negative effects on health care, impacting patients and health care workers alike.